Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...

Novartis has lost its legal challenge against the Inflation Reduction Act on Friday, making it the sixth drugmaker rejected ...

The FDA on Friday approved Astellas’ treatment for a type of gastric cancer, marketed as Vyloy (zolbetuximab). The approval ...

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

The European Medicines Agency’s human medicines committee again decided not to recommend the renewal of the conditional ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

CVS Health is parting ways with CEO Karen Lynch as the pharmacy giant continues to struggle with problems in its insurance ...

Supernus Pharmaceuticals' mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially ...